Milestone Pharmaceuticals to Present at H.C. Wainwright BioConnect Conference

Event summary

  • Milestone Pharmaceuticals will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, in New York.
  • The presentation will be a live webcast available to conference participants at 3:00 PM ET.
  • Milestone’s lead product, CARDAMYST™ (etripamil) nasal spray, is FDA-approved for treating acute symptomatic episodes of PSVT.
  • Etripamil is also in development for controlling symptomatic episodic attacks associated with AFib-RVR.

The big picture

Milestone Pharmaceuticals’ presentation at the H.C. Wainwright BioConnect Conference underscores its focus on advancing cardiovascular therapies. The company’s FDA-approved CARDAMYST and ongoing development of etripamil for AFib-RVR position it within a growing market for innovative cardiovascular treatments. The event provides a platform for Milestone to engage with investors and highlight its strategic direction in a competitive biopharmaceutical landscape.

What we're watching

Product Pipeline
How the development of etripamil for AFib-RVR will impact Milestone’s commercial strategy.
Market Positioning
Whether Milestone can differentiate itself in the competitive cardiovascular therapeutics space.
Investor Sentiment
The pace at which investor interest in Milestone’s pipeline and commercialization efforts grows post-conference.